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Background/objective: The objective of this study was to investigate the safety and efficacy of 
subcutaneous (SC) and intravenous (IV) tanezumab administration in osteoarthritis (OA) patients.
Materials and methods: Study 1027 (NCT01089725), a placebo-controlled trial, evaluated 
the efficacy of SC tanezumab (ie, 2.5, 5, and 10 mg) and the therapeutic equivalence of 10 mg 
tanezumab given subcutaneously versus intravenously every 8 weeks in the symptomatic treat-
ment of OA. Coprimary endpoints were: change from baseline in Western Ontario and McMaster 
Universities Osteoarthritis index (WOMAC) Pain and Physical Function indices, and Patient’s 
Global Assessment (PGA) of OA. Study 1043 (NCT00994890) was a long-term, noncontrolled 
safety study of tanezumab (ie, 2.5, 5, and 10 mg) subcutaneously administered every 8 weeks. 
Both studies were discontinued prematurely due to a US Food and Drug Administration partial 
clinical hold. 
Results: Due to the clinical hold, Study 1027 was underpowered, and no statistical analyses 
were performed. Mean (standard error [SE]) change from baseline to week 8 in WOMAC Pain 
in tanezumab groups ranged from −3.59 (0.26) to −3.89 (0.32), versus −2.74 (0.25) with pla-
cebo. Mean (SE) change from baseline to week 8 in WOMAC Physical Function ranged from 
−3.13 (0.25) to −3.51 (0.28) with tanezumab and was −2.26 (0.24) with placebo. PGA mean 
(SE) change from baseline to week 8 ranged from −0.90 (0.11) to −1.08 (0.12) with tanezumab 
and was −0.78 (0.10) with placebo. Similar effectiveness was associated with tanezumab in 
Study 1043. Few patients in either study (1.4%–5.2%) discontinued due to adverse events. Five 
patients required total joint replacements in Study 1027 (placebo, n=2 [2.8%]; tanezumab 2.5 
mg, n=3 [4.1%]) and 34 patients in Study 1043 (tanezumab 2.5 mg, n=11 [4.8%]; tanezumab 
5 mg, n=8 [3.6%]; tanezumab 10 mg, n=15 [6.6%]). 
Conclusion: Preliminary results show similar efficacy and safety for both SC and IV admin-
istration of tanezumab based on the direct comparisons reported here and indirect comparisons 
with published results, confirming pharmacokinetic/pharmacodynamic modeling predictions.
Keywords: tanezumab, subcutaneous, osteoarthritis, efficacy, safety
Plain language summary
Tanezumab is in development for the treatment of chronic pain conditions. While tanezumab 
has been administered via intravenous (IV) injection in most clinical studies performed to 
date, subcutaneous (SC) administration is more convenient and therefore preferred. Therefore, 
in order to determine whether SC tanezumab is also efficacious in the symptomatic treatment 
of osteoarthritis (OA) pain, two clinical trials examined the efficacy and safety of tanezumab 
administered by SC injection, as well as the therapeutic equivalence of 10 mg SC tanezumab 
versus 10 mg IV injection. In both the studies, all tanezumab doses were associated with similar 
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improvements in pain, function, and patient’s overall global assess-
ment of OA. SC tanezumab had a favorable safety profile in both the 
studies. These studies provide preliminary evidence that the efficacy 
and safety of SC tanezumab is similar to that of IV administration.
Introduction
Nerve growth factor (NGF) is a key modulator of pain sig-
naling,1 and chronic pain is often associated with increased 
NGF.1–4 Tanezumab, a humanized monoclonal antibody, 
tightly binds NGF with high selectivity and specificity,2,5 
thereby inhibiting NGF binding to its receptors (tropomyosin 
receptor kinase A [high-affinity receptor] and p75 [low-
affinity receptor]).4 In clinical studies of osteoarthritis (OA) 
pain, tanezumab produced significant, clinically meaningful 
improvements in pain, function, and global assessments, with 
an acceptable safety profile.6–13
The pharmacokinetic (PK) profile of subcutaneous (SC) 
tanezumab is dose-linear across the 2.5–10 mg dose range, 
with ~70% bioavailability compared with intravenous (IV) 
administration across all doses.14 To determine whether the 
tanezumab dose needs to be adjusted when converting from 
IV to SC administration, simulations were performed to pre-
dict weekly pain score over time using fixed-effect population 
parameter estimates from PK14 and PK/pharmacodynamic 
(PD) models.15 The simulations predicted that tanezumab 
concentrations are maintained above the model-estimated 
IC
50
 after SC and IV administration. Although the predicted 
mean change from baseline to week 1 in weekly pain score 
was lower with SC compared with IV dosing, this difference 
decreased with increasing dosage. In addition, the predicted 
difference between tanezumab SC and IV was <5% by 
week 4, suggesting no dosing adjustment is needed when 
converting to SC administration. 
In order to confirm tanezumab SC and IV administration 
produce similar clinical response, two clinical trials inves-
tigated the efficacy and safety of SC tanezumab in patients 
with moderate-to-severe OA of the knee or hip. Since PK/
PD simulations suggested that analgesia onset differed with 
SC administration, an additional objective was to determine 
whether the analgesia profile for SC administration was 
similar across doses. Pharmacokinetics and immunogenicity 
were also evaluated.
Materials and methods
Studies 1027 and 1043 were conducted in compliance with 
the Declaration of Helsinki and International Conference on 
Harmonisation Good Clinical Practice guidelines. Protocols 
and informed consent documentation were reviewed and 
approved by Schulman Associates Institutional Review Board 
(Cincinnati, OH, USA) for all sites in Study 102724 and all 
but two sites in Study 1043.25 The two additional institutional 
review boards utilized in Study 1043 were Health Science 
Institutional Review Board (Columbia, MO, USA) and Grant 
Medical Centre Institutional Review Board (Columbus, OH, 
USA). Patients provided written informed consent before 
undergoing any procedures. Treatment was discontinued on 
June 23, 2010, following a partial clinical hold placed by 
the US Food and Drug Administration (FDA) due to adverse 
events related to joint safety.16
Study 1027
Study 102724 was a randomized, double-blind, double-dummy, 
placebo-controlled, multicenter, parallel-group trial designed 
to evaluate the efficacy and safety of tanezumab administered 
subcutaneously every 8 weeks in patients with knee OA 
(ClinicalTrials.gov identifier: NCT01089725; Figure 1A). 
The primary objectives were to demonstrate the efficacy of 
tanezumab SC administration versus placebo and therapeutic 
equivalence of tanezumab 10 mg SC and IV administration. 
Study population
Patients in Study 102724 were aged ≥18 years with a diag-
nosis of OA of the knee based on the American College 
of Rheumatology criteria and radiographic confirmation 
(Kellgren– Lawrence X-ray grade ≥2)17–19 and Western 
Ontario and McMaster Universities Osteoarthritis Index 
(WOMAC) Pain score ≥4 at screening and ≥5 at baseline 
(on a 0–10 numeric rating scale [NRS]) in the index knee. 
Patients regularly taking pain medications (≥4 days per week) 
during the month prior to screening had to have an increase 
of ≥1 point in WOMAC Pain score between screening and 
baseline. Patients were also required to have WOMAC Physi-
cal Function score ≥4 (0–10 NRS) in the index knee; Patient’s 
Global Assessment (PGA) of OA of “fair,” “poor,” or “very 
poor” at baseline; and ≥1 of the following: unwilling or 
unable to take nonopiate pain medications (eg, nonsteroidal 
anti-inflammatory drugs [NSAIDs]), inadequate pain relief 
with nonopiate pain medications, or candidates for seeking 
invasive interventions (ie, intra-articular injections, knee 
arthroplasty, or knee replacement surgery).
Key exclusion criteria for Study 1027 were similar to pre-
vious tanezumab studies.6,7 They included pregnancy, nursing, 
or intent to become pregnant during the study; body mass 
index >39 kg/m2; history of joint disease or recent trauma 
to the index knee; significant incapacitation, fibromyalgia, 
or regional pain caused by lumbosacral radiculopathy; 
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 significant cardiac, neurologic, or psychiatric conditions; 
planned surgery during the study; or previous exposure to 
exogenous NGF or NGF antibody. 
Study design and treatments
Study 1027 consisted of a screening period (up to 30 days 
prior to randomization), including washout (minimum 2-day 
washout, if required), initial pain assessment (3 days prior 
to randomization/baseline), treatment lasting 16 weeks, and 
follow-up of 8 weeks (Figure 1A). Patients were randomized 
in a 3:3:3:4:4 ratio to placebo SC plus placebo IV, tanezumab 
2.5 mg SC plus placebo IV, tanezumab 5 mg SC plus placebo 
IV, tanezumab 10 mg SC plus placebo IV, and tanezumab 10 
mg IV plus placebo SC administered at 8-week intervals. 
Tanezumab or corresponding placebo was administered 
by IV infusion preferably in the antecubital fossa. All patients 
received 5 mL of study medication (1 mL of study medica-
tion plus 4 mL of sodium chloride injection, United States 
Pharmacopeia [USP]) administered over 5 minutes without 
infusion pump (slow IV push) followed with an IV flush of 
5 mL of sodium chloride for injection, USP. The SC injec-
tions consisted of 1 mL of study medication (tanezumab or 
Figure 1 Study design. (A) Study 102724 and (B) Study 1043.25
Abbreviations: BL, baseline; IV, intravenous; OA, osteoarthritis; PGA, Patient’s Global Assessment; SC, subcutaneous; WOMAC, Western Ontario and McMaster 
Universities Osteoarthritis Index.
Placebo SC plus placebo IV (n=150)
Screening
Week
BL 4 8 16 24 32 40 48 56 64
–30 1 29 57 113 169 225 281 337 393 449
BL pain:
Days –3 to –1
Randomization
and first dose of
study medication
Second dose of
study medication
End of study
Primary endpoint = change from BL
to week 16 in WOMAC pain, WOMAC
physical function, and PGA of OA
–30 –3 1 15 29 57 85 113 169
BL 2 4 8 12 16 24
Study day
Tanezumab 2.5 mg SC plus placebo IV (n=150)
Tanezumab 5 mg SC plus placebo IV (n=150)
Tanezumab 10 mg SC plus placebo IV (n=200)
Tanezumab 2.5 mg (n=230)
Screening
Week
Study Day
Randomization
SC administration of study drug End of
treatment/early
termination
End of study
Tanezumab 5 mg (n=222)
Tanezumab 10 mg (n=226)
Placebo SC plus tanezumab 10 mg IV (n=200)
A
B
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corresponding placebo) injected in the abdomen or anterior 
aspect of the thigh.
Efficacy
Efficacy was assessed as a change from baseline to week 
16 in three coprimary endpoints: WOMAC Pain, WOMAC 
Physical Function, and PGA of OA. WOMAC scores were 
recorded on an 11-point NRS (higher scores indicated greater 
pain or functional impairment); PGA was recorded on a 
5-point scale (1 =very good, 5 =very poor).20,21 Secondary 
endpoints included the percentage of patients with ≥30%, 
≥50%, ≥70%, and ≥90% improvements from baseline in 
WOMAC Pain and the percentage of patients considered 
responders using the Outcome Measures in Rheumatology 
Arthritis Clinical Trials–Osteoarthritis Research Society 
International (OMERACT-OARSI) responder index (defined 
as a ≥50% change and ≥2-point absolute change on either 
WOMAC Pain or WOMAC Physical Function subscales or 
≥20% change and ≥1-point absolute change for at least two 
of the three coprimary endpoints).22
Statistical analysis
Efficacy and safety analyses for Study 1027 were based on 
the intent-to-treat (ITT) population (all patients randomized 
and treated with at least one SC or IV dose). For the three 
coprimary endpoints, the number and percentage of patients 
in each response category were summarized by treatment and 
time on an observed case basis using last observation car-
ried forward imputation for missing data. The total planned 
sample size was 850 patients. 
In order to determine whether tanezumab was superior 
to placebo, a sample size of 150 patients per treatment 
was required to provide 90% power to achieve statistical 
significance at the 5% two-sided level for comparisons of 
tanezumab 5 and 10 mg SC versus placebo over all three 
coprimary endpoints. This sample size would yield ~80% 
power to achieve statistical significance for all three tan-
ezumab SC doses versus placebo comparisons over all 
three coprimary endpoints. In order to establish therapeutic 
equivalence of tanezumab 10 mg SC and IV over all three 
coprimary endpoints, a sample size of 200 patients in the 
tanezumab 10 mg SC and tanezumab 10 mg IV groups was 
needed to provide ~90% power. The margins against which 
the 90% confidence limits were to be compared were set to 
±1.0 for WOMAC Pain and Physical Function indices and 
±0.4 for PGA of OA. In addition, therapeutic equivalence 
required point estimates for the difference in least squares 
mean to fall within one-half of the corresponding confidence 
limit bounds. Therefore, the total planned sample size to meet 
both the primary objectives was 850 patients.
Since Study 1027 was not fully enrolled due to the partial 
clinical hold, the sample size was insufficient to meet study 
objectives; therefore, no statistical hypothesis testing was 
performed. Changes to planned analyses were made prior 
to unblinding of the study.
Study 1043
Study 104325 was a randomized, double-blind, parallel-group, 
multicenter, long-term safety trial of tanezumab 2.5, 5, and 
10 mg SC in patients with moderate-to-severe knee or hip 
OA (ClinicalTrials.gov identifier: NCT00994890; Figure 1B).
Study population
Inclusion criteria were identical to Study 1027 except that 
patients with OA of the hip were eligible to participate in 
the study, there were no requirements regarding intolerance 
or inability to take other analgesics, WOMAC Pain score ≥4 
(instead of ≥5) at baseline, and patients regularly (average 
≥4 days per week) used an opioid or nonopioid analgesic 
for OA pain. 
Key exclusion criteria for Study 1043 were largely 
similar to Study 1027 and included pregnancy, nursing, or 
intent to become pregnant during the study; body mass index 
>39 kg/m2; history of joint disease or recent trauma to the 
index knee or hip; significant incapacitation, fibromyalgia, or 
regional pain caused by lumbosacral radiculopathy; signifi-
cant cardiac, neurologic, or psychiatric conditions; planned 
surgery during the study; or previous exposure to exogenous 
NGF or NGF antibody.
Study design and treatments
Patients in Study 1043 were randomized in equal allocation 
to SC tanezumab 2.5, 5, or 10 mg administered at 8-week 
intervals (seven doses total) for up to ~1 year; placebo treat-
ment and tanezumab IV administration were not included in 
this study. Approved prescription analgesics, over-the-counter 
analgesics, or muscle relaxants as concomitant analgesic 
medications for OA were permitted. Tanezumab injections 
(1 mL) were administered subcutaneously in the abdomen 
or anterior aspect of the thigh using the same formulation 
as Study 1027.
Efficacy
Efficacy was assessed as a change from baseline to various 
time points in WOMAC Pain; WOMAC Physical Function; 
PGA of OA; the percentage of patients with ≥30%, ≥50%, 
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≥70%, and ≥90% improvements in WOMAC Pain; and the 
percentage of OMERACT-OARSI responders.
Statistical analysis
Efficacy and safety were assessed in the ITT population. 
There were no statistical comparisons among groups. Last 
observation carried forward imputation was used for missing 
data for efficacy analyses. A sample size of 200 patients per 
group (600 patients in total) provided 95% probability of at 
least one patient with an individual adverse event where the 
true adverse event rate was ~1.5%.
Both studies
Safety
Safety assessments in both the studies included adverse 
event documentation, vital signs, physical and neurologic 
examinations, 12-lead electrocardiogram, injection site 
assessment, and laboratory test results. Injection and infu-
sion site assessments were conducted 1 hour postdose and at 
follow-up assessments. If an injection/infusion site reaction 
was observed, further assessments were carried out to moni-
tor resolution. Study investigators performed standardized 
neurologic examinations at each clinic visit. If a neurologic 
adverse event was reported or clinically significant change 
was noted on examination, the patient was referred to a neu-
rologist for further evaluation. Following the implementation 
of the partial clinical hold, a blinded external adjudication 
committee, consisting of orthopedic surgeons, rheuma-
tologists, and an orthopedic pathologist, convened to review 
adverse events reported as total joint replacement (TJR) and 
all adverse events initially reported as osteonecrosis. 
Blood samples were collected at baseline (Day 1) in both 
the studies; at weeks 8, 16, and 24 (or early termination; Study 
1027); and weeks 8, 24, and 40 (or early termination; Study 
1043) for the assessment of antidrug antibodies (ADAs). 
Serum ADA analysis followed a tiered approach using 
screening, confirmation, and titer/quantitation in a validated 
semi-quantitative enzyme-linked immunosorbent Fab assay 
(ELISA; ICON Development Solutions LLC, Whitesboro, 
NY, USA). ADA-positive samples were analyzed in a neu-
tralizing antibody (NAb) binding assay to characterize the 
response. Samples were considered positive if the titer was 
at or above the assay limit of detection (log
2
 of the minimum 
required 20-fold dilution [4.32]).
Pharmacokinetics
Blood samples (3–4 mL) were collected for tanezumab PK 
assessments at baseline (predose; both studies); weeks 1, 2, 
4, 8 (predose), 12, 16, and 24 (or early termination) in Study 
1027; and at weeks 2, 8 (predose), 24 (predose), 40 (predose), 
or early termination in Study 1043. Plasma samples were 
analyzed by using a validated, sensitive, and specific ELISA 
(ICON Development Solutions).
Results
Study 1027
Overall, 379 patients (45% of the planned population) were 
randomized, treated with study medication, and comprised 
the ITT population (Figure 2A). Baseline characteristics 
were similar across treatments (Table 1). Due to <10% of 
patients receiving a second dose at week 8, efficacy results 
are described for change from baseline to week 8 only. Mean 
duration of treatment (108.4–113.5 days) was similar across 
treatment groups.
Efficacy
Mean (standard error [SE]) change from baseline to week 8 
in WOMAC Pain score in the tanezumab groups ranged from 
−3.59 (0.26) to −3.89 (0.32); the corresponding change with 
placebo was −2.74 (0.25) (Figure 3A). Mean (SE) change 
from baseline to week 8 in WOMAC Physical Function score 
ranged from −3.13 (0.25) to −3.51 (0.28) with tanezumab 
and −2.26 (0.24) with placebo (Figure 3B). For PGA of OA 
score, mean (SE) change from baseline to week 8 was −0.90 
(0.11) to −1.08 (0.12) with tanezumab and −0.78 (0.10) with 
placebo (Figure 3C). Inspection of the efficacy–time curves 
indicated onset and duration of analgesia with all SC doses 
were similar to the 10 mg IV dose over the 8-week dosing 
interval.
The percentage of patients with ≥30%, ≥50%, ≥70%, 
and ≥90% reductions in WOMAC Pain score at week 8 was 
greater in all tanezumab groups versus placebo (Figure 3D). 
These differences were more pronounced at the ≥70% and 
≥90% levels. The percentage of patients with OMERACT-
OARSI response at week 8 was greater with tanezumab 
dosing than with placebo (Figure 3E).
Safety
Overall, the incidence of all-causality adverse events in 
Study 1027 was highest with tanezumab 10 mg IV and 
placebo versus tanezumab 2.5 and 5 mg SC (Table 2). No 
deaths occurred. Five treatment-emergent serious adverse 
events were reported: two each in the tanezumab 2.5 mg SC 
(2.7%) and placebo groups (2.8%) and one (1.2%) in the 
tanezumab 10 mg IV group (Table 2). The most frequent 
adverse events (≥5% of patients in any group) included 
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Figure 2 Patient disposition in (A) Study 102724 and (B) Study 1043.25 
Note: aTermination due to partial clinical hold placed by US FDA. 
Abbreviations: FDA, Food and Drug Administration; IV, intravenous; SC, subcutaneous.
Screened
n=1080
Excluded
n=695
Randomized to
placebo but not
treated
n=0
Randomized to and
treated with
placebo
n=72
Discontinued, n (%)
  Adverse event, 1 (1.4)
  Lack of efficacy, 4 (5.6)
  Lost to follow-up, 2 (2.8)
  No longer willing to take
  part in study, 5 (6.9)
  Protocol violation, 0 (0.0)
  Study terminated by
  sponsor, 51 (70.8)a
  Other, 3 (4.2)
Completed study, 6 (8.3)
Discontinuations from study, n (%)
  Adverse event, 13 (5.7)
  Lack of efficacy, 0 (0.0)
  No longer willing to participate
  in study, 8 (3.5)
  Lost to follow-up, 6 (2.6)
  Protocol violation, 2 (0.9)
  Other, 2 (0.9)
Study terminated by sponsor, 199 (85.5)a
Completed study, 0 (0.0)
Discontinuations from study, n (%)
  Adverse event, 11 (4.9)
  Lack of efficacy, 1 (0.4)
  No longer willing to participate
  in study, 13 (5.8)
  Lost to follow-up, 3 (1.3)
  Protocol violation, 0 (0.0)
  Other, 1 (0.4)
Study terminated by sponsor, 197 (87.2)a
Completed study, 0 (0.0)
Discontinued, n (%)
  Adverse event, 1 (1.4)
  Lack of efficacy, 3 (4.1)
  Lost to follow-up, 2 (2.7)
  No longer willing to take
  part in study, 5 (6.8)
  Protocol violation, 0 (0.0)
  Study terminated by
  sponsor, 56 (75.7)a
  Other, 0 (0.0)
Completed study, 7 (9.3)
Discontinued, n (%)
  Adverse event, 0 (0.0)
  Lack of efficacy, 1 (1.6)
  Lost to follow-up, 0 (0.0)
  No longer willing to take
  part in study, 4 (6.3)
  Protocol violation, 1 (1.6)
  Study terminated by
  sponsor, 53 (84.5)a
  Other, 0 (0.0)
Completed study, 4 (6.2)
Discontinued, n (%)
  Adverse event, 0 (0.0)
  Lack of efficacy, 0 (0.0)
  Lost to follow-up, 3 (3.5)
  No longer willing to take
  part in study, 5 (5.8)
  Protocol violation, 1 (1.2)
  Study terminated by
  sponsor, 68 (79.1)a
  Other, 1 (1.2)
Completed study, 5 (9.2)
Discontinued, n (%)
  Adverse event, 2 (2.4)
  Lack of efficacy, 4 (4.8)
  Lost to follow-up, 0 (0.0)
  No longer willing to take
  part in study, 4 (4.8)
  Protocol violation, 0 (0.0)
  Study terminated by
  sponsor, 65 (81.0)a
  Other, 0 (0.0)
Completed study, 6 (7.0)
Randomized to and
treated with
tanezumab 2.5 mg SC
n=74
Randomized to and
treated with
tanezumab 5 mg SC
n=63
Randomized to and
treated with
tanezumab 10 mg SC
n=86
Randomized to and
treated with
tanezumab 10 mg IV
n=84
Randomized to
tanezumab
2.5 mg SC but
not treated
n=1
Randomized to
tanezumab
5 mg SC but
not treated
n=2
Randomized to
tanezumab
10 mg SC but
not treated
n=1
Randomized to
tanezumab
10 mg IV but
not treated
n=2
Assigned to treatment
n=385
Patients evaluated
at weeks 8, 26 (36.1%)
Patients evaluated
at weeks 8, 23 (31.1%)
Patients evaluated
at weeks 8, 34 (54.0%)
Screened
n=1259
Excluded
n=580
Assigned to treatment
n=679
Randomized to
tanezumab 2.5 mg
but not treated
n=1
Randomized to
tanezumab 5 mg
but not treated
n=0
Randomized to
tanezumab 10 mg
but not treated
n=0
Randomized to and
treated with
tanezumab 10 mg SC
n=226
Randomized to and
treated with
tanezumab 5 mg SC
n=222
Randomized to and
treated with
tanezumab 2.5 mg SC
n=230
Patients evaluated
at week 16, n=115
Patients evaluated
at week 16, n=135
Patients evaluated
at week 16, n=118
Patients evaluated
at weeks 8, 42 (48.8%)
Patients evaluated
at weeks 8, 36 (42.9%)
Discontinuations from study, n (%)
  Adverse event, 9 (4.1)
  Lack of efficacy, 0 (0.0)
  No longer willing to participate
  in study, 5 (2.3)
  Lost to follow-up, 1 (0.5)
  Protocol violation, 4 (1.8)
  Other, 2 (0.9)
Study terminated by sponsor, 201 (90.5)a
Completed study, 0 (0.0)
A
B
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arthralgia,  paresthesia, hypoesthesia, worsening OA, head-
ache, and joint swelling; two of these events (paresthesia and 
hypoesthesia) occurred only in patients receiving tanezumab. 
Injection site reaction incidence was generally low (≤4.7%) 
across treatments. Most reactions were mild in severity; 
none were severe.
Adverse events of abnormal peripheral sensation reported 
in >2% of patients in any group were paresthesia, hypoes-
thesia, burning sensation, and sensory disturbance (Table 2). 
Most patients (≥95%) had no new or worsened abnormalities 
at final neurologic examination (Table 2).
No adverse events of osteonecrosis were reported by 
investigators. Five patients underwent TJR: two placebo-
treated patients and three patients receiving tanezumab 2.5 
mg SC. One event reviewed by the adjudication committee 
was judged as normal progression of OA. The other four 
events were not reviewed due to lack of radiographic images.
Pharmacokinetics and anti-tanezumab antibodies
Overall, in Study 1027, PK descriptive summaries and 
individual profiles of tanezumab suggest that absorption 
and disposition of SC tanezumab were similar across doses. 
Tanezumab was slowly absorbed, with maximum plasma con-
centrations generally occurring within 1–2 weeks of the first 
injection (Figure 4). The increase in median peak and trough 
(week 8) concentrations was approximately proportional to 
dose. Because of the clinical hold, most patients received 
only a single dose following which median plasma concen-
trations of tanezumab declined exponentially throughout the 
remainder of the study period.
Table 1 Patient demographic characteristics, duration of disease, and doses of study medication administered
Study 102724 Study 104325
Placebo  
n=72
Tanezumab Tanezumab 
2.5 mg SC  
(n=74)
5 mg SC  
(n=63)
10 mg SC  
(n=86)
10 mg IV  
(n=84)
2.5 mg SC 
(n=230)
5 mg SC  
(n=222)
10 mg SC  
(n=226)
Gender, n (%)
Female 47 (65.3) 48 (64.9) 36 (57.1) 54 (62.8) 48 (57.1) 152 (66.1) 157 (70.7) 161 (71.2)
Age, mean (range), 
years
61.3 (25–84) 61.0 (21–84) 60.3 (32–81) 58.2 (40–83) 59.6 (24–87) 61.7 (38–89) 62.4 (36–91) 63.4 (27–94)
Weight, mean (SD), kg 85.6 (17.4) 86.7 (17.2) 90.8 (19.0) 90.7 (14.8) 90.0 (16.1) 87.8 (17.0) 85.4 (17.0) 89.0 (17.5)
BMI, mean (SD), kg/m2 30.8 (5.4) 30.5 (4.8) 31.0 (4.8) 31.7 (4.3) 30.7 (4.5) 30.8 (4.7) 30.7 (5.0) 31.7 (4.8)
Race, n (%)
White 60 (83.3) 60 (81.1) 51 (81.0) 73 (84.9) 73 (86.9) 197 (85.7) 191 (86.0) 193 (85.4)
Black 10 (13.9) 9 (12.2) 8 (12.7) 10 (11.6) 5 (6.0) 25 (10.9) 22 (9.9) 29 (12.8)
Asian 2 (2.8) 4 (5.4) 2 (3.2) 2 (2.3) 4 (4.8) 1 (0.4) 4 (1.8) 3 (1.3)
Other 0 (0.0) 1 (1.4) 2 (3.2) 1 (1.2) 2 (2.4) 7 (3.0) 5 (2.3) 1 (0.4)
Index joint, n (%)
Knee 72 (100) 74 (100) 63 (100) 86 (100) 84 (100) 183 (79.6) 190 (85.6) 186 (82.3)
Hip 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 47 (20.4) 32 (14.4) 40 (17.7)
Kellgren–Lawrence grade n (%)
0 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (<1.0) 0 (0.0)
1 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (<1.0) 0 (0.0) 0 (0.0)
2 33 (45.8) 32 (43.2) 25 (39.7) 40 (46.5) 44 (52.4) 80 (34.8) 75 (33.8) 71 (33.4)
3 26 (36.1) 31 (41.9) 31 (49.2) 34 (39.5) 32 (38.1) 111 (48.3) 102 (45.9) 116 (51.3)
4 13 (18.1) 11 (14.9) 7 (11.1) 12 (14.0) 8 (9.5) 38 (16.5) 43 (19.4) 39 (17.3)
Duration since the diagnosis of OA, years
Mean (range) 9.6 (0−51) 7.3 (0−41) 9.1 (0−50) 8.7 (0−47) 8.2 (0−40) 8.4 (0–45) 8.7 (0–42) 7.3 (0–50)
Number of doses administered
1 65 67 56 78 77 48 36 38
2 7 7 7 8 7 99 89 103
3 0 0 0 0 0 64 72 61
4 0 0 0 0 0 19 25 24
Duration of treatment, days
Mean (range) 110.7 
(8−180)
110.2 
(8−170)
111.3 
(8−176)
113.5 
(9−176)
108.4 
(8−170)
180.3 
(14−345)
190.8 
(15−311)
187.2  
(14−333)
Abbreviations: BMI, body mass index; IV, intravenous; OA, osteoarthritis; SC, subcutaneous; SD, standard deviation.
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The immunogenicity profile was favorable, with only 2.3% of 
patients testing positive for the presence of ADA in the four tan-
ezumab treatment groups. Among 827 serum samples screened 
(from 307 patients in total), 294 samples were  presumptively 
ADA-positive, and on further testing, only 11 samples (in seven 
patients) were confirmed as ADA-positive. Upon titer/quantita-
tion analysis, nine samples had titer results >4.32. One patient was 
considered baseline positive with no increase in titer postdose, 
Figure 3 Study 1027:24 Mean (SE) change from baseline in (A) WOMAC Pain, (B) WOMAC Physical Function, and (C) PGA of OA; (D) percentage of patients with ≥30%, 
≥50%, ≥70%, and ≥90% reduction from baseline in WOMAC pain scores; and (E) OMERACT-OARSI response at week 8 (ITT, LOCF). 
Abbreviations: BL, baseline; ITT, intent-to-treat; IV, intravenous; LOCF, last observation carried forward; OA, osteoarthritis; OMERACT-OARSI, Outcome Measures in 
Rheumatology Arthritis Clinical Trials–Osteoarthritis Research Society International; PGA, Patient’s Global Assessment; SC, subcutaneous; SE, standard error; WOMAC, 
Western Ontario and McMaster Universities Osteoarthritis Index.
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and six patients had treatment-induced ADA with low titers 
(4.62–8.18). The nine ADA-positive samples were analyzed in 
the NAb assay; five were negative for Nab, whereas four (from 
three patients) were confirmed Nab-positive with low titers 
(5.82–10.1). Individual profiles indicated no apparent alterations 
in tanezumab concentrations, efficacy, or incidence and severity 
of adverse events for the seven ADA-positive patients compared 
with patients who were ADA-negative.
Study 1043
A total of 678 patients were randomized and treated in Study 
1043 (Figure 2B). Demographics and baseline characteristics 
were comparable across treatments; most (~80%) patients 
received at least two of the seven planned tanezumab SC 
injections (Table 1). Mean treatment duration was similar 
across treatments (180.3–190.8 days).
Efficacy
Fewer than half of the patients in Study 1043 received more 
than two tanezumab treatments; therefore, efficacy results 
are presented only through week 16. Tanezumab treatment 
resulted in improvements from baseline to week 16 in 
WOMAC Pain, WOMAC Physical Function, and PGA of 
OA scores (Figure 5A–C); similar improvements were seen 
Table 2 Treatment-emergent adverse events (observed data) and summary of final neurologic consultations (ITT population, observed 
data)
Adverse events and final neurologic 
consultations
Study 102724 Study 104325
Placebo 
(n=72)
Tanezumab Tanezumab
2.5 mg SC 
(n=74)
5 mg SC 
(n=63)
10 mg SC 
(n=86)
10 mg IV 
(n=84)
2.5 mg SC 
(n=230)
5 mg SC 
(n=222)
10 mg SC 
(n=226)
Patients with AEs 37 (51.4) 35 (47.3) 31 (49.2) 36 (41.9) 44 (52.4) 158 (68.7) 169 (76.1) 181 (80.1)
Patients with SAEs 2 (2.8) 2 (2.7) 0 (0.0) 0 (0.0) 1 (1.2) 17 (7.4) 12 (5.4) 20 (8.8)
Patients discontinued due to AEs 1 (1.4) 1 (1.4) 0 (0.0) 0 (0.0) 2 (2.4) 12 (5.2) 9 (4.1) 11 (4.9)
AEs reported in ≥5% in any groupa
Arthralgia 4 (5.6) 4 (5.4) 7 (11.1) 5 (5.8) 5 (6.0) 37 (16.1) 30 (13.5) 27 (11.9)
Paresthesia 0 (0.0) 1 (1.4) 2 (3.2) 6 (7.0) 6 (7.1) 13 (5.7) 17 (7.7) 25 (11.1)
Peripheral edema 0 (0.0) 1 (1.4) 3 (4.8) 4 (4.7) 3 (3.6) 9 (3.9) 16 (7.2) 22 (9.7)
Injection site reaction 2 (2.8) 2 (2.7) 0 (0.0) 4 (4.7) 3 (3.6) 19 (8.3) 21 (9.5) 20 (8.8)
Urinary tract infection 0 (0.0) 2 (2.7) 0 (0.0) 2 (2.3) 0 (0.0) 11 (4.8) 12 (5.4) 20 (8.8)
Osteoarthritis 5 (6.9) 4 (5.4) 0 (0.0) 1 (1.2) 0 (0.0) 8 (3.5) 12 (5.4) 19 (8.4)
Pain in extremity 2 (2.8) 1 (1.4) 3 (4.8) 4 (4.7) 3 (3.6) 14 (6.1) 12 (5.4) 16 (7.1)
Hypoesthesia 0 (0.0) 2 (2.7) 1 (1.6) 6 (7.0) 2 (2.4) 14 (6.1) 6 (2.7) 15 (6.6)
Joint swelling 4 (5.6) 1 (1.4) 2 (3.2) 3 (3.5) 1 (1.2) 8 (3.5) 10 (4.5) 13 (5.8)
Fall 0 (0.0) 2 (2.7) 1 (1.6) 1 (1.2) 1 (1.2) 7 (3.0) 5 (2.3) 12 (5.3)
Musculoskeletal pain 0 (0.0) 2 (2.7) 2 (3.2) 2 (2.3) 2 (2.4) 8 (3.5) 15 (6.8) 12 (5.3)
Upper respiratory tract infection 0 (0.0) 2 (2.7) 1 (1.6) 0 (0.0) 2 (2.4) 12 (5.2) 9 (4.1) 12 (5.3)
Headache 3 (4.2) 5 (6.8) 0 (0.0) 5 (6.8) 2 (2.4) 9 (3.9) 6 (2.7) 10 (4.4)
AEs of abnormal peripheral sensation in ≥2% in any groupa,b
Paresthesia 0 (0.0) 1 (1.4) 2 (3.2) 6 (7.0) 6 (7.1) 13 (5.7) 17 (7.7) 25 (11.1)
Hypoesthesia 0 (0.0) 2 (2.7) 1 (1.6) 6 (7.0) 2 (2.4) 14 (6.1) 6 (2.7) 15 (6.6)
Burning sensation 0 (0.0) 1 (1.4) 2 (3.2) 0 (0.0) 2 (2.4) 1 (0.4) 5 (2.3) 2 (0.9)
Sensory disturbance 0 (0.0) 0 (0.0) 0 (0.0) 2 (2.3) 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.9)
Final neurologic consultation categorizationc
Patients referred for consultation 0 (0.0) 3 (4.1) 4 (6.3) 8 (9.3) 7 (8.3) 29 (12.6) 34 (15.3) 45 (19.9)
Suggestive of new or worsened peripheral 
neuropathy based on symptoms, signs, or 
diagnostic tests
0 (0.0) 2 (2.7) 2 (3.2) 6 (7.0) 3 (3.6) 11 (4.8) 10 (4.5) 17 (7.5)
Not suggestive of neuropathy 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.2) 1 (1.2) 5 (2.2) 6 (2.7) 7 (3.1)
Neurologic signs or symptoms suggestive 
of a pre-existing neuropathy
0 (0.0) 1 (1.4) 1 (1.6) 1 (1.2) 1 (1.2) 8 (3.5) 6 (2.7) 11 (4.9)
No neurologic symptoms or signs 0 (0.0) 0 (0.0) 1 (1.6) 0 (0.0) 2 (2.4) 5 (2.2) 12 (5.4) 10 (4.4)
Notes: All values presented as n (%) unless otherwise noted. aPresentation order based on incidence in Study 104325 tanezumab 10 mg SC group. bAEs of abnormal peripheral 
sensation included allodynia, axonal neuropathy, burning sensation, decreased vibratory sense, demyelinating polyneuropathy, dysesthesia, formication, hyperesthesia, 
hyperpathia, hypoesthesia, hypoesthesia facial, hypoesthesia oral, intercostal neuralgia, neuralgia, neuritis, neuropathy peripheral, paresthesia, paresthesia oral, peripheral 
sensorimotor neuropathy, peripheral sensory neuropathy, polyneuropathy, polyneuropathy chronic, sensory disturbance, sensory loss, and thermohypoesthesia. cNeurologic 
consultations performed by neurologists following neurologic adverse event report or significant neurologic examination abnormalities detected by investigators.
Abbreviations: AE, adverse event; ITT, intent-to-treat; IV, intravenous; SAE, serious adverse event; SC, subcutaneous.
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at week 8. More patients treated with tanezumab 5 and 10 
mg had ≥30%, ≥50%, ≥70%, and ≥90% improvements in 
WOMAC Pain score than with tanezumab 2.5 mg; however, 
differences between tanezumab 10 and 5 mg were minimal 
(Figure 5D). The percentage of OMERACT-OARSI respond-
ers was highest in patients treated with tanezumab 10 mg 
(Figure 5E).
Safety
Adverse events in Study 1043 occurred at higher rates with 
tanezumab 10 mg than with tanezumab 2.5 or 5 mg (Table 2). 
The number of patients experiencing at least one serious 
adverse event was higher in the tanezumab 10 mg group than 
in the tanezumab 2.5 or 5 mg groups (Table 2). The most 
frequently investigator-reported serious adverse events were 
arthralgia (n=8; 4, 1, and 3 patients in the tanezumab 2.5, 
5, and 10 mg treatment groups, respectively), osteonecrosis 
(n=9; 1, 4, and 4 patients in the tanezumab 2.5, 5, and 10 mg 
treatment groups, respectively), and worsening OA (n=7; 2, 1, 
and 4 patients in the tanezumab 2.5, 5, and 10 mg treatment 
groups, respectively). Discontinuation due to an adverse 
event was highest in the tanezumab 2.5 mg group (Table 2). 
Arthralgia was the most frequent reason for discontinua-
tion (tanezumab 2.5 mg, n=2 [0.9%]; tanezumab 5 mg, n=2 
[0.9%]; tanezumab 10 mg, n=1 [0.4%]). No deaths occurred.
Injection site reaction incidence was generally low 
(≤9.5% in each group), although slightly higher than in 
Study 1027. The most frequent injection site reactions were 
ecchymosis and erythema. Most injection site reactions were 
mild, and none were severe. 
Adverse events of abnormal peripheral sensation occurred 
at higher incidence in the tanezumab 10 mg group (Table 2). 
Most adverse events of abnormal peripheral sensation 
resolved before last patient contact. Most (≥81.7%) patients 
had no new or worsened abnormality at final neurologic 
examination (Table 2).
Nine patients (tanezumab 2.5 mg, n=1 [0.4%]; tanezumab 
5 mg, n=4 [1.8%]; tanezumab 10 mg, n=4 [1.8%]) in Study 
1043 had an adverse event initially reported as osteonecrosis 
(Figure 6) by the investigator. Eight of these patients had 
documented evidence of preexisting OA in the affected joint. 
Overall, 34 patients (tanezumab 2.5 mg, n=11 [4.8%]; tan-
ezumab 5 mg, n=8 [3.6%]; tanezumab 10 mg, n=15 [6.6%]) 
reported TJR (all-cause). This included all nine patients with 
Figure 4 Study 1027:24 Individual observed (symbols) and predicted 5th (lower dashed black line), 50th (solid black line), and 90th (upper dashed black line) percentiles 
tanezumab concentrations over the first 8 weeks in patients who received a 2.5 mg SC, 5 mg SC, 10 mg SC, or 10 mg IV dose of tanezumab. 
Abbreviations: IV, intravenous; SC, subcutaneous.
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reported osteonecrosis plus an additional 25 patients. Of these 
34 patients, 32 (94%) took NSAIDs at some time while they 
were treated with tanezumab.
Twenty-two patients, including all nine patients with 
adverse events initially reported as osteonecrosis and 13 
patients with all-cause TJR, in Study 1043 were reviewed by 
Figure 5 Study 1043:25 Mean (SE) change from baseline in (A) WOMAC Pain, (B) WOMAC Physical Function, and (C) PGA of OA; percentage of patients with (D) ≥30%, 
≥50%, ≥70%, and ≥90% reduction from baseline in WOMAC pain scores at weeks 8 and 16; and (E) OMERACT-OARSI response at week 16 (ITT, LOCF). 
Abbreviations: BL, baseline; ITT, intent-to-treat; IV, intravenous; LOCF, last observation carried forward; OA, osteoarthritis; OMERACT-OARSI, Outcome Measures in 
Rheumatology Arthritis Clinical Trials–Osteoarthritis Research Society International; PGA, Patient’s Global Assessment; SC, subcutaneous; SE, standard error; WOMAC, 
Western Ontario and McMaster Universities Osteoarthritis Index.
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adjudication committee. No patients were judged as having 
osteonecrosis. Twenty patients were adjudicated to worsening 
OA: 10 to normal progression of OA, nine to rapid progres-
sion of OA, and one as worsening OA (insufficient informa-
tion to distinguish between rapid and normal progression; 
Figure 6). Two patients were adjudicated as another diagnosis 
(one with preexisting femoral neck fracture [tanezumab 10 
mg] and the other had long-standing OA [tanezumab 5 mg]). 
All nine patients adjudicated to rapid progression of OA 
reported concomitant NSAID use during the study.
Long-term SC tanezumab treatment was not associated 
with meaningful changes in clinical laboratory values, vital 
signs, or electrocardiographic results.
Pharmacokinetics and anti-tanezumab antibodies
The PK profile in Study 1043 was comparable to Study 
1027, as was the immunogenicity profile, with only 1.3% of 
patients testing positive for the presence of ADA across the 
three  treatment groups. Of the 2021 serum samples tested 
(from 675 patients), 368 samples were presumptively ADA-
positive, of which 17 samples (from nine patients) were 
positive upon confirmatory assay. Of these, 15 samples (nine 
patients) had titer results ≥4.32 (5.12–15.54). Three of the 
nine patients were baseline ADA-positive with no significant 
increase in titer postdose, while six patients had treatment-
induced ADA. Six of the 15 samples screened positive for 
Nab, with five samples (from four patients) confirming 
positive with low titers (5.61–9.93). Individual profiles indi-
cated no apparent differences in tanezumab concentrations, 
efficacy, or safety for the nine ADA-positive patients versus 
ADA-negative patients.
Discussion
Two studies were conducted to demonstrate the efficacy 
and safety of SC tanezumab in patients with moderate-to-
severe OA pain. Study 1027 was also designed to evaluate 
Figure 6 Study 1043:25 Adjudication outcomes of joint safety events. 
Abbreviations: AE, adverse event; OA, osteoarthritis; ON, osteonecrosis; SC, subcutaneous; TJR, total joint replacement.
Patients not adjudicated, n=0
9/9 (100%) 13/25 (52%)
Patients not adjudicated, n=12
X-rays unavailable, n=10
Reported TJR after cutoff date,
n=2
Other diagnosis, n=2
Preexisting femoral neck
fracture, knee, (tanezumab
10 mg SC), n=1
Long-standing  OA
(tanezumab 5 mg SC), n=1
Patients with TJR or investigator-
reported AEs of ON, n=34
Tanezumab 2.5 mg SC, n=11
Tanezumab 5 mg SC, n=8
Tanezumab 10 mg SC, n=15
Patients with reported ON
Tanezumab 2.5 mg SC, n=1
Tanezumab 5 mg SC, n=4
Tanezumab 10 mg SC, n=4
Patient adjudicated, n=22
Tanezumab 2.5 mg SC, n=7
Tanezumab 5 mg SC, n=6
Tanezumab 10 mg SC, n=9
Worsening OA, n=20
Tanezumab 2.5 mg SC, n=7
Tanezumab 5 mg SC, n=5
Tanezumab 10 mg SC, n=8
Normal progression of OA, n=10
Tanezumab 2.5 mg SC, n=4
Tanezumab 5 mg SC, n=2
Tanezumab 10 mg SC, n=4
Rapid progression of OA, n=9
Tanezumab 2.5 mg SC, n=3
Tanezumab 5 mg SC, n=3
Tanezumab 10 mg SC, n=3
Insufficient information to determine
rate of progression, n=1
Tanezumab 2.5 mg SC, n=0
Tanezumab 5 mg SC, n=0
Tanezumab 10 mg SC, n=1
Patients with TJR not associated with ON
Tanezumab 2.5 mg SC, n=34
Tanezumab 5 mg SC, n=4
Tanezumab 10 mg SC, n=34
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 therapeutic equivalence of SC and IV tanezumab 10 mg. 
Due to the partial clinical hold, enrollment in Study 1027 
was insufficient to yield adequate power to fulfill the pri-
mary objectives, and no statistical hypothesis testing was 
performed. However, qualitative inspection of results at 
week 8 indicates tanezumab SC and IV were associated 
with improvements in pain, physical function, and global 
well-being compared with placebo.
Onset and duration of analgesia over the 8-week dos-
ing interval with all SC doses of tanezumab in both studies 
were similar to the tanezumab 10 mg IV dose in Study 1027. 
Moreover, the magnitude of response and analgesic profile 
observed with tanezumab 10 mg IV was similar to previously 
published studies in patients with OA of the knee or hip in 
which the enrollment objectives were fully met.6–8 Thus, the 
efficacy profile of tanezumab SC appears similar to IV admin-
istration based on a qualitative comparison in Study 1027 and 
an indirect comparison to previously published results.6–13 
In Study 1043, tanezumab 5 and 10 mg resulted in similar 
improvements from baseline at weeks 8 and 16, and these 
improvements were larger than those in the tanezumab 2.5 mg 
group. Benefit with tanezumab 10 mg over 5 mg was mini-
mal. These results are also consistent with prior studies.6–13
SC tanezumab had a favorable safety profile in both the stud-
ies. Overall incidence and types of adverse events reported were 
generally comparable to IV administration in OA patients.6,7,9–13 
Incidence of injection site reactions was generally low across 
both the studies, although slightly higher in Study 1043 due to 
longer study duration and additional dosing. A slightly higher 
incidence of injection site reactions was reported relative to 
other tanezumab studies conducted with IV administration 
only6–13 – suggesting a difference in the profile between SC 
and IV administration – but may be due, at least in part, to the 
more detailed injection site assessment in those studies. Most 
injection site reactions in the current two studies were mild; 
none were severe. Across treatments, the incidence of serious 
adverse events and discontinuations due to adverse events were 
low. No events were adjudicated as primary osteonecrosis. The 
vast majority of patients had no significant abnormality on 
neurologic examination at their final assessment. 
Overall, PK descriptive summaries and individual profiles 
of tanezumab suggest that absorption and disposition of SC 
tanezumab were similar across 2.5, 5, and 10 mg doses and 
that exposure increases linearly with dose. As expected, 
the average tanezumab plasma concentrations in the first 4 
weeks after dosing were slightly lower with 10 mg SC than 
with 10 mg IV administration, but (as PK/PD simulations 
suggested) did not decrease efficacy.
During the conduct of clinical OA pain studies of tanezumab 
and other NGF inhibitors, a signal event initially described 
by investigators as osteonecrosis often leading to TJR raised 
concerns about joint-related safety of tanezumab and led to a 
partial clinical hold on the entire NGF inhibitor class by the US 
FDA. Reports of osteonecrosis and all other TJRs underwent 
careful and thorough investigation by an independent expert 
adjudication committee.23 No evidence was found to indicate 
that tanezumab was associated with an increased risk of osteo-
necrosis, a disease process distinct from OA, although a risk 
of rapidly progressive OA was identified.16 In our studies, nine 
patients were adjudicated to rapid progression of OA; all had 
taken concomitant NSAIDs during the study. Thus, similar to 
other reported studies,11 the risk of rapidly progressive OA with 
tanezumab was greatest when coadministered with NSAIDs.
The incidence of anti-tanezumab antibodies was low. 
Based on ADA incidence in IV studies, the SC route is not 
more immunogenic than IV infusion. Individual patient 
profiles indicated no apparent alterations in tanezumab con-
centrations, efficacy, or incidence and severity of adverse 
events in patients who were ADA-positive compared with 
patients negative for ADA. 
A significant limitation of these studies was the impact 
of the clinical hold on the duration and enrollment of both 
the studies, resulting in the insufficiency to yield adequate 
statistical power to fulfill the primary objectives in Study 
1027 and a reduction in the number of tanezumab doses 
administered in Study 1043.
Conclusion
Although these studies were limited by the partial clinical 
hold, the data provide preliminary evidence that the efficacy 
and safety of SC tanezumab is generally similar to IV admin-
istration in patients with OA pain.
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